

1 Tereza Grimmichova^{1, 2}, Ludmila Verespejova³, Zuzana Urbaniova³, Martin Chovanec³, Martin Hill¹,

2 Radovan Bilek¹

3 ¹Institute of Endocrinology, Prague, Czech Republic

4 ²Department of Internal medicine, Faculty Hospital Kralovske Vinohrady and Third Faculty of

5 Medicine, Charles University, Prague, Czech Republic

6 ³Department of Otorhinolaryngology, Faculty Hospital Kralovske Vinohrady and Third Faculty of

7 Medicine, Charles University, Prague, Czech Republic

8

9 **Title: Acquired hypothyroidism, iodine status and hearing impairment in adults: a pilot study.**

10 **Short title: Hypothyroidism, iodine status and hearing impairment**

11

12 ***Corresponding author:** tgrimmichova@endo.cz

13

14 **Author contributions:** TG conceived the study, analyzed data and wrote the paper. LV, ZU examined
15 the patients. MH made the statistics. MCH, RB made the supervision.

16

17 **Acknowledgements:** The authors acknowledge D. Hardekopf for proofreading activity.

18

19

20

21

22

23

24

25

26

27

28 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

29 **Abstract**

30 **Objectives:** Hearing impairment can have major impacts on behavior, educational attainment, social
31 status, and quality of life. In congenital hypothyroidism, the incidence of hearing impairment reaches
32 35-50%, while in acquired hypothyroidism there is a reported incidence of 25%. Despite this,
33 knowledge of the pathogenesis, incidence and severity of hearing impairment remains greatly
34 lacking. The aim of our study was to evaluate hearing in patients with acquired hypothyroidism.

35 **Methods:** 30 patients with untreated and newly diagnosed peripheral hypothyroidism (H) and a
36 control group of 30 healthy probands (C) were enrolled in the study. Biochemical markers were
37 measured, including median iodine urine concentrations (IUC) $\mu\text{g/L}$. The hearing examination
38 included a subjective complaint assessment, otomicroscopy, tympanometry, transitory otoacoustic
39 emission (TOAE), tone audiometry, and brainstem auditory evoked potential (BERA) examinations.
40 The Mann-Whitney U test, Fisher's Exact test and multivariate regression were used for statistical
41 analysis.

42 **Results:** The H and C groups had significantly different thyroid hormone levels (medians with 95% CI)
43 TSH mU/L 13.3 (8.1, 19.3) vs. 1.97 (1.21, 2.25) $p=0$ and fT4 pmol/L 10.4 (9.51, 11.1) vs. 15 (13.8, 16.7)
44 $p=0$. The groups did not significantly differ in age 39 (34, 43) vs. 41 (36,44) $p=0.767$ and IUC 142 (113,
45 159) vs. 123 (101, 157) $p=0.814$. None of the hearing examinations showed differences between the
46 H and C groups: otomicroscopy ($p=1$), tympanometry ($p=1$), TOAE ($p=1$), audiometry ($p=0.179$), and
47 BERA ($p=0.505$).

48 **Conclusions:** We did not observe any hearing impairment in adults with acquired hypothyroidism,
49 and there were no associations found between hearing impairment and the severity of
50 hypothyroidism or iodine status. However, some forms of hearing impairment, mostly mild, were
51 very common in both studied groups.

52

53

54

55 **Introduction**

56 Hypothyroidism can occur in countries that have sufficient iodine supplementation, with
57 autoimmune thyroiditis the most common cause [1]. Patients with hypothyroidism report hearing
58 losses; however, hearing impairments are poorly recognized and underreported, and often explicitly
59 associated with congenital hypothyroidism and iodine deficiency [2]. It is well known that hearing
60 deficits have a great impact on the education skills and social status of children and adolescents [3].
61 Youth with hearing impairments experience behavioral problems and demonstrate lower
62 performance in oral language compared with peers with normal hearing [4]. Unfortunately, only
63 limited studies have been dedicated to acquired hypothyroidism and hearing disabilities in adults [2,
64 5, 6].

65 The development of ears and their functioning depends on thyroid hormones. Thyroid
66 hormones are necessary for maturation of the cochlea and the central auditory areas [7]. In humans,
67 the critical period for hearing maturation corresponds approximately to an interval ranging from the
68 early embryonic period to the first year of postnatal life [2]. Hypothyroidism occurring during this
69 critical time window can lead to irreversible hearing impairment [8, 9]. However, when thyroxine (T4)
70 therapy is begun early enough in life, it might still successfully reverse hearing loss [10]. Iodine is an
71 essential component of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). Thyroid
72 hormone receptors (TR), occurring as the two isoforms TR α and TR β , regulating thyroid hormone
73 metabolism at the transcriptional level are expressed in the cochlea [11, 12]. Genetic disorders such
74 as Pendred syndrome [13], thyroid hormone resistance [14], and thyroid hormones monocarboxylate
75 transporter 8 abnormalities [15] support the links between thyroid hormones and the auditory
76 system. The most well-known is Pendred syndrome, caused by biallelic mutations in the
77 *SLC26A4/PDS* gene, which encodes the multifunctional anion exchanger pendrin. Pendred syndrome
78 is an autosomal recessive disorder that is classically defined by the combination of sensorineural
79 deafness/hearing impairment, goiter, and an abnormal organification of iodide with or without

80 hypothyroidism [13, 16]. Importantly, Pendred syndrome accounts for about 4–10% of all cases of
81 hereditary deafness. The hallmark of the syndrome is impaired hearing, which is associated with
82 inner ear malformations such as an enlarged vestibular aqueduct [17, 18]. The organification defect
83 is only mild and only seems to result in hypothyroidism under iodine-deficient conditions. Therefore,
84 it remains unclear whether the sensorineural hearing loss associated with Pendred syndrome is
85 solely caused by hypothyroidism [12, 13, 18].

86 Overall, it seems that hearing impairment associated with acquired hypothyroidism are most
87 often bilateral, symmetrical, and sensorineural (perceptive), with some studies also supporting a
88 conductive loss, and reversible to varying degrees after levothyroxine replacement therapy [6, 19].
89 Bircher was the first to describe the association of hearing impairment in patients suffering from a
90 goiter as early as 1883 [20]. Various investigators have reported an association between thyroid
91 hormone concentrations and hearing function in humans, but many of these studies are from the last
92 century. In the 1950s, a study by Howarth and Lloyd 1956 described deafness under hypothyroidism
93 as perceptive in type, with hypertrophy and edema of the mucosa of the nose, middle ear and
94 eustachian tubes causing eustachian obstruction and thickening of the tympanic membrane. The
95 study included seven females aged from 31-75 years with various levels of conductive hearing
96 impairments (slight 0-20 dB loss to very severe perceptive deafness over 60 dB loss) and
97 demonstrated improvements in some patients after thyroid hormone substitution [21]. In the 1970s
98 the study Bhatia et al. 1977 confirmed hypothyroidism using estimates of serum protein-bound
99 iodine in 43% of patients (total 72 patients) who had mild hearing loss as assessed by pure tone
100 audiometry [22]. In the 1980s, twenty hypothyroid patients were investigated, demonstrating
101 hearing losses in 80% of patients when compared with randomly selected age- and sex-matched
102 normal subjects. Following treatment with levothyroxine a statistically significant improvement in
103 hearing thresholds was observed by pure-tone audiometry. The investigators suggested a causal
104 relationship between hypothyroidism and hearing loss [5]. In 2002, Malik et al. also reported a higher
105 degree of hearing impairments in forty-five hypothyroid patients (age range 10–57 years). Pure tone

106 audiometry (PTA) revealed hearing impairments in thirty-two patients, out of which fifteen had
107 conductive, nine had mixed and eight had sensorineural impairments. Hearing impairment was
108 correlated with increasing serum TSH levels and decreasing serum T3 and T4 levels ($p > 0.05$).
109 Brainstem Evoked Response Audiometry (BERA) was performed in patients having hearing
110 impairments shown by PTA. The interpeak interval (I-V) was >4.0 ms in 81.80% of ears, and the
111 waves were not well formed with lower amplitude. After treatment with levothyroxine, hearing
112 thresholds were significantly better in 30% of ears, with conductive impairment more likely to be
113 improved [6]. This is in agreement with the findings of Bhatia et al 1977 who observed that the
114 occurrence of hearing impairment gradually increased with an increase in the severity of
115 hypothyroidism. The vestibular system was found to be affected only minimally [22]. Similar results
116 but to a lesser extent were shown in a study by Aggarwal et al., with only about 13% cases having an
117 objective audiological improvement, though many cases claimed a subjective improvement in
118 hearing after thyroid hormone substitution. One case also had a deterioration in hearing [23]. In
119 contrast, some studies have shown no hearing impairment in hypothyroid patients [24, 25] and
120 others have not supported associations between hearing impairment and thyroid hormone levels in
121 hypothyroid patients [26, 27].

122 Further, the evidence does suggest that iodine deficiency is related to hearing loss, and that
123 supplementation in iodine-deficient individuals may improve hearing thresholds. Auditory
124 impairment due to hypothyroidism causing such an iodine deficiency might exist [3]. The National
125 Health and Nutrition Examination Survey is a cross-sectional, nationally representative survey of the
126 noninstitutionalized civilian population of the United States analyzing data from 1198 adolescent
127 (aged 12-19 years) participants. Urinary iodine concentration (UIC) less than $100 \mu\text{g/L}$ was found to
128 be a predictive risk factor for having speech-frequency hearing loss among adolescents and more
129 specifically among those with UICs less than $50 \mu\text{g/L}$. However, the geometric mean of thyrotropin
130 concentration of $1.4 \mu\text{UI/mL}$ was in the normal range [28, 29]. In adults however, even less is about
131 acquired hypothyroidism in relation to auditory function.

132 The aims of our study were to assess:

133 1) hearing impairment in relation to acquired hypothyroidism and associated changes to thyroid
134 hormone levels.

135 2) hearing impairment due to iodine status as measured by median urinary iodine concentrations.

136 3) the risks of hearing loss and associations with the severity of hypothyroidism, including whether or
137 not the severity of deafness is proportional to the degree of hypothyroidism and/or urinary iodine
138 concentrations.

139

140 **Patients and Methods**

141 The protocol of this prospective study complied with the Declaration of Helsinki and was approved by
142 the Ethic Committee of the Faculty Hospital Kralovske Vinohrady. Before entering the study, written
143 informed consent was obtained by the investigator from patients after they received both written
144 and oral information. Patients' history, medical records, ultrasound of the neck (US), and biochemical
145 testing were done at two workplaces: the Institute of Endocrinology and the Department of Internal
146 Medicine of the University Hospital Kralovske Vinohrady in Prague. Hearing tests were done at the
147 Department of Otorhinolaryngology of the University Hospital Kralovske Vinohrady in Prague. A total
148 of 30 hypothyroid patients and 30 matched healthy probands without history/treatment of thyroid
149 disease were enrolled in the study [30]. The patients were all from the Czech Republic, a country with
150 iodine sufficiency, and were consecutively recruited from 25th May 2021 to 21st February 2024. The
151 inclusion and exclusion criteria are given in the study flow chart in Figure 1.

152


153

154

155

156

157 **Figure 1 Flow chart of the study.**



158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

Overt primary hypothyroidism is defined as thyroid-stimulating hormone (TSH) concentrations above the reference range and free thyroxine (T4) concentrations below the reference range. The diagnosis of overt hypothyroidism was confirmed by a second blood sample. All the probands underwent the same study protocol with the same examinations. Biochemical testing consisted of measurement of electrolytes, liver and kidney tests, blood count, lipids, glucose, and Hb1ac to exclude diabetes, dyslipidemia, and systemic disease with impact on hear loss. Three consecutive morning urine samples were taken to measure median urinary iodine concentrations (UICs). UIC is an indicator of iodine status and reflects the current dietary intake of iodine. Urinary iodine below 20 µg/L denotes severe iodine deficiency, between 20–49 moderate, between 50–99 mild iodine deficiency, UIC between 100–199 is adequate iodine intake, UIC between 200–299 more than adequate, and UIC more than 300 µg/L is excessive iodine intake [31]. The WHOQOL-BREF questionnaire was used to evaluate the quality of life [32]. The hearing examination consisted of descriptions of subjective symptoms (tinnitus, dizziness, feeling of hear loss, and balance problem) and objective hearing exams: tympanometry (Maico MI 24), pure tone audiometry (Clinical Audiometer AC 40 Interacoustic), transitory otoacoustic emission (TOAE) (Titan Interacoustic) and Brain Evoked Response Audiometry (BERA) (Eclipse Interacoustic). Hearing losses were classified as either: mild (20 - 34 dB); moderate (35

175 - 49 dB); moderately severe (50 - 64 dB), severe (65-79 dB), profound (80-94 dB), or as complete
176 hearing loss (> 95 dB). The Global Burden of Disease (GBD) scale defines hearing loss as the quietest
177 sound an individual can hear in their better ear, taken as the pure-tone average (PTA) of audiometric
178 thresholds of 0.5 kHz, 1 kHz, 2 kHz, and 4 kHz [33, 34]. Serum TSH (0.270-4.200 mIU/L), fT4 (11.9-21.6
179 pmol/L), fT3 (3.10-6.80 pmol/L), TRAbs (0.00-1.75 IU/L), thyroglobulin (3.50-77.00 ug/L)
180 concentrations were measured using the ECLIA method (Roche). The HbA1C test was performed using
181 an ion exchange HPLC method that is certified by the NGSP (www.njsp.org) and standardized or
182 traceable to the Diabetes Control and Complications Trial (DCCT) reference assay. Serum anti-Tg (0.01-
183 120.00 IU/mL) and anti-TPO (0.01-40.00 IU/mL) were measured by ELISA (Aeskulisa). Urinary iodine
184 concentrations were measured by absorption spectrophotometry at a wavelength of 430 nm. Glucose
185 was measured by a spectrophotometry (UV)-hexokinase method. Liver enzymes and lipids were
186 measured by absorption spectrophotometry (Cobas PRO, Roche), and blood count (Celtac F, Nihon
187 Kohden).

188 **Statistics**

189 Statistical significance was defined as p-values <0.05. The Mann-Whitney U test ((medians with
190 95% CI) and Fisher's Exact test were used for statistical analysis. The importance of individual
191 predictors in discriminating between individual groups was evaluated using multivariate regression
192 with a reduction of dimensionality known as orthogonal projections to latent structure (OPLS) for one
193 predicted (dependent) variable in the model [35].

194

195 **Results**

196 A total of 60 patients were enrolled in the study, but two patients had to be excluded: one
197 hypothyroid patient due to newly diagnosed severe iron deficiency anemia and one control proband
198 due to newly diagnosed polycythemia vera. Finally, 29 hypothyroid patients (H; 21 women and 8
199 men) and 29 controls (C; 25 women and 4 men) were statistically analyzed. The H and C groups were
200 not statistically different in either age (medians with 95% CI) 39 (34, 43) vs. 41 (36, 44) ($p=0.767$) or

201 gender ($p=0.331$). The H group had significantly higher levels than the C group of: TSH 13.3 (8.1, 19.3)
202 vs. 1.97 (1.21, 2.25) mU/L ($p=0$); anti-TPO 335 (164, 520) vs. 28 (4.78, 31) IU/mL ($p < 0.01$); and anti-
203 Tgl IU/mL 32.6 (4.88, 58.6) vs. 1.3 (1.3, 1.3) IU/mL ($p<0.001$). The H group had significantly lower fT4
204 10.4 (9.51, 11.1) vs. 15 (13.8, 16.7) pmol/L ($p=0$) and fT3 4.61 (4.35, 5.1) vs. 5.24 (5.07, 5.5) pmol/L
205 ($p=0.009$) compared to the C group. For more details see Table 1.

206

207 **Table 1.** The Mann-Whitney test was used to compare the control and hypothyroid groups.

Variable	Control group (median 95% CI)	Hypothyroid group (median 95% CI)	p-value
Age	41 (36, 44)	39 (34, 43)	0.767
BMI kg/m ²	23 (21.6, 23.9)	25.6 (24, 28.3)	0.08
WHOQOL-BREF	97 (94,102)	95 (91, 104)	0.63
TSH mIU/L	1.97 (1.21, 2.25)	13.3 (8.1, 19.3)	0
fT4 pmol/L	15 (13.8, 16.7)	10.4 (9.51, 11.1)	0
fT3 pmol/L	5.24 (5.07, 5.5)	4.61 (4.35, 5.1)	0.009
anti-TPO IU/mL	28 (4.78, 31)	335 (164, 520)	<0.001
anti-Tgl IU/mL	1.3 (1.3, 1.3)	32.6 (4.88, 58.6)	<0.001

TRAK IU/L	0.91 (0.8, 0.97)	0.86 (0.8, 1.19)	0.986
Thyroglobulin ug/L	12.7 (8.85, 24.5)	8.29 (1.34, 26.4)	0.217
UIC ug/L	123 (101, 157)	142 (113, 159)	0.814
Thyroid volume mL	9.38 (8.6, 10.5)	11.9 (10, 13.2)	0.019
Total cholesterol mmol/L	4.67 (4.47, 4.84)	5.51 (5.29, 6.11)	<0.001
LDL cholesterol mmol/L	2.84 (2.38, 3.1)	3.46 (2.95, 3.83)	0.003
HDL cholesterol mmol/L	1.6 (1.55, 1.69)	1.49 (1.26, 1.8)	0.643
Triglycerides mmol/L	1.07 (0.85, 1.17)	1.37 (1.04, 1.69)	0.009
Glucose mmol/L	5.1 (4.68, 5.33)	5.01 (4.7, 5.52)	1
HbA1c mmol/mol	33.5 (32, 35)	33 (32, 36)	1
Vitamin D nmol/L	59.6 (57.4, 74)	70.1 (50.9, 84.9)	0.508

208 WHOQOL-BREF - a questionnaire for quality of life, TRAK - thyroid-stimulating hormone receptor

209 antibodies, IUC - iodine urine concentration.

210

211 The cause of hypothyroidism was autoimmune thyroiditis (p=0). The H and C groups were

212 comparable in IUCs 142 (113, 159) vs. 123 (101, 157) µg/L (p=0.814). Only 15 probands had mild

213 iodine deficiencies, with the lowest IUC of 50 µg/L. For more details see Table 2.

214

215 **Table 2.** Fisher's exact 2-sided test was used to compare the control and hypothyroid groups.

Variable	Control group	Hypothyroid group	p-value
Male	13.8%	27.6%	0.331
Smoking	3.7%	18.2%	0.160
Autoimmune thyroiditis	3.4%	86.2%	0
Otomicroscopy	0%	3.4%	1
Tympanometry	6.9%	6.9%	1
Audiometry	27.6%	10.3%	0.179
GBD R	3.4%	0%	1
GBD L	3.4%	0%	1
BERA	13.8%	21.4%	0.505

216 GBD R - GBD scale right ear, GBD L - GBD scale left ear, BERA - brainstem evoked response

217 audiometry.

218 Out of the 58 patients in the study group, only 3 patients in the C group presented with

219 subjective complaints, including unilateral hearing loss and tinnitus. There were no subjective

220 complaints in the H group ($p=0.239$). Otomicroscopy revealed no pathologies except for one case of
221 an atrophic eardrum ($p=1$). Some hearing impairment in the patients was observed in 29 patients, of
222 which 17 were in the hypothyroid group and 12 control probands. Hearing impairments
223 predominantly affected high-tone frequencies (6 kHz and 8 kHz) in the range from 20-45dB. We did
224 not observe any deficiency of more than 45 dB. The hearing examinations tympanometry ($p=1$),
225 TOAE ($p=1$), audiometry ($p=0.179$), and BERA ($p=0.505$) were not different between the H and C
226 groups. For more details see Table 2 and 3.

227

228 **Table 3. The Mann-Whitney test was used to compare the control and hypothyroid groups.**

Variable	Control group (median 95% CI)	Hypothyroid group (median 95% CI)	p-value
PTA R (dB)	9 (8,10)	8 (6,9)	0.120
PTA L (dB)	9 (8, 10)	9 (6,10)	0.456
Audiometry 6 kHz R (dB)	10 (10, 15)	10 (10,15)	0.833
Audiometry 6 kHz L (dB)	10 (10, 20)	15 (10,15)	0.768
Audiometry 8kHz R (dB)	10 (10,15)	15 (10, 20)	0.387
Audiometry 8kHz L (dB)	10 (10, 20)	15 (10,20)	0.880

229 PTA R - pure-tone average right ear, PTA L - pure-tone average left ear. R - right ear, L - left ear.

230

231 The OPLS statistical analysis used to evaluate the importance of individual predictors to discriminate

232 between the hypothyroid and control groups found no statistically significant predictors of hearing
233 impairments.

234

235 **Discussion**

236 In our study, we did not observe any hearing impairments related to acquired
237 hypothyroidism in adults. Further our data did not support any associations between hearing
238 impairment and the degree of hypothyroidism and iodine status. However, some forms of hearing
239 impairment, mostly mild, were very common in both studied groups.

240 The prevalence of overt hypothyroidism in the general population varies between 0–2% and
241 3-5% in Europe, and the prevalence of undiagnosed hypothyroidism, including both overt and mild
242 cases, is around 5%. In iodine-sufficient areas, the most common cause of hypothyroidism is chronic
243 autoimmune thyroiditis [36]. We concur with these results and we have to point out that we had
244 some difficulties finding a patient with manifest hypothyroidism. Only three patients had TSH levels
245 over 50 mU/L. The probable reason was that our patient cohorts were younger, but widespread
246 thyroid function testing and relatively low thresholds for treatment initiation almost certainly also
247 play a role [37].

248 Hearing impairment is a major public health problem and is one of the leading causes of
249 years lived with a disability. Moreover, according to the World Health Organization, the incidence of
250 auditory disorders is increasing at an alarming rate without much concern or perception by society or
251 public health officials [38]. Hearing impairments can affect the quality of life from childhood, with
252 poor school performance common, as well as in adulthood, with higher risks of unemployment or
253 lower earnings [39]. Hearing impairment is also associated with increased cognitive dysfunction and
254 dementia in the elderly [40]. There are many reasons for hearing impairment in adults and it is
255 strongly associated with age. We chose to study younger probands (<50 years old) in order to
256 eliminate the risks of presbycusis, metabolic disorders such as type 2 diabetes, obesity, hypertension

257 and dyslipidemia with their associated negative effects on hearing [39, 41]. Not surprisingly, our
258 hypothyroid group of probands had higher lipids levels compared to the control group, but without
259 any impact on hearing impairment. The majority of probands were non-smokers, so this risk factor
260 was not relevant in this study. In comparison to some other studies [6, 22, 5] we can just speculate
261 on the divergent results. Most of the studies were done in the past, and recent studies are mostly
262 from India and the Middle East [26, 42, 43]. This geographical variation could introduce several
263 confounding factors, including the prevalence of occupational noise exposure, preventable infections
264 such as chronic otitis media and meningitis, nutritional status and health-care access. Further, there
265 is evidence of improvements in hearing between 1959–1962 and 1999–2004, suggesting a beneficial
266 trend for at least half a century. Explanations for this trend could include reductions in occupational
267 noise exposure, less smoking, and better management of other cardiovascular risk factors such as
268 hypertension and diabetes [33].

269 Previous studies were also frequently done with a small number of probands with ages
270 ranging from 12 to 75 years old. Further, the hypothyroid status of probands tended to be very
271 heterogeneous, from subclinical forms to severe myxedema [44]. In the study of Malik et al., 2002,
272 moderate hearing impairment was present approximately in 48% and mild impairment in 41% of
273 ears, whereas severe or profound hearing impairment was not found in any case [6]. In agreement
274 with previous studies, we observed mostly mild and only two cases with moderate hearing
275 impairments in both hypothyroid and control groups. In later studies, hearing examinations were
276 usually more detailed than thyroid testing and evaluations of iodine status [6, 42, 26]. Some other
277 nutritional factors such as single nutrients (vitamin A, B, C, D and E, and zinc, Mg, Se, iodine, and iron)
278 are associated with hearing status. Serum thyroglobulin is well correlated with the severity of iodine
279 deficiency as measured by median urinary iodine concentrations (UICs) [45], but our groups had
280 comparable levels of both thyroglobulin and UICs in the optimal range. Based on WHO data, the
281 number of countries with iodine insufficiency has declined from 113 (estimated by total goiter rates)
282 in 1993 to 20 (estimated by urinary iodine concentrations) in 2017 [46]. Congenital iodine deficiency

283 can be manifested as two syndromes: a more common neurological disorder with brain damage,
284 deaf mutism, squint and spastic paresis of the legs. Such patients are usually euthyroid, but goiter
285 and hypothyroidism can be seen in some cases. Urinary iodine levels are usually less than 20 µg/L.
286 The less common syndrome includes severe hypothyroidism and growth retardation but a less severe
287 mental defect. Both conditions are due to dietary iodine deficiency and can be prevented by iodine
288 supplementation before pregnancy [47]. Hearing loss has also been observed in adolescents (aged
289 12-19 years) associated with iodine deficiency in spite of normal TSH levels [28]. Therefore, it
290 remains uncertain whether the hearing loss is solely caused by hypothyroidism or iodine deficiency.
291 It appears that iodine plays a role in immune responses and might have a beneficial influence on
292 mammary dysplasia and fibrocystic breast disease [48]. It is possible that iodine itself could have
293 some other roles in human physiology.

294 One of the limits of our study is the low number of probands, but this was rather a pilot
295 study about a topic with very limited evidence. We also did not retest the patients after thyroxine
296 replacement therapy reaching euthyroidism, since there were no significant differences between the
297 hypothyroid and control groups in hearing impairments. There are some previous studies showing
298 significant improvement of hearing threshold in 12.5 up to 73% ears at several levels, middle ear,
299 cochlear or retro-cochlear [42]. Bhatia et al 1979 reported definite subjective improvement in
300 hearing on becoming euthyroid, but this was not confirmed by audiometry. Another limit of our
301 study could be that the hypothyroid state was not too advanced in our patients. All of our
302 hypothyroid patients complied with the definition of hypothyroidism, i.e. increased levels of TSH and
303 simultaneously decreased fT4 levels in spite of fT3 being in normal range in some of the probands.
304 There are adaptive mechanisms during iodine deficiency, or the incipient phase of hypothyroidism,
305 preserving optimal plasma and tissue T3 levels linked to deiodinase 2 expression. The signs and
306 symptoms of overt hypothyroidism are minimized by preserving T3 levels. Thus, serum T3 levels
307 perform poorly as a tool to diagnose hypothyroidism compared to serum FT4 or TSH. Nevertheless, it
308 is clear that plasma and tissue T3 contents are associated and that changes in plasma T3 are directly

309 connected to changes in the tissue T3 content [49]. We cannot exclude that patients with parallel
310 drops in T4 and T3 levels could be at risk of hearing impairments, but our statistical analysis did not
311 observe any links between thyroid hormone levels and such impairment. A benefit of our study is the
312 prospective design with comprehensive examinations of patients and excluding more common
313 causes of hearing loss. We included evaluations of iodine status, which has a crucial effect on hearing
314 impairment. Finally, the quality of life of our probands established by the WHOQOL-BREF
315 questionnaire was comparable for both groups.

316 **Conclusions**

317 We did not observe any hearing impairment in adults associated with acquired hypothyroidism.
318 However, some forms of hearing impairment, mostly mild, were very common in both studied
319 groups. Since our study did not show any associations between hearing impairment and either the
320 severity of hypothyroidism or iodine status, we suppose that there are more important causes of
321 hearing impairment than hypothyroidism in adults.

322

323 **References:**

- 324 1. Ragusa F, Fallahi P, Elia G, Gonnella D, Paparo SR, Giusti C, et al. Hashimotos' thyroiditis:
325 Epidemiology, pathogenesis, clinic and therapy. *Best Pract Res Clin Endocrinol Metab.*
326 2019;33: 101367.
- 327 2. Melse-Boonstra A, Mackenzie I. Iodine deficiency, thyroid function and hearing deficit: a
328 review. *Nutr Res Rev.* 2013;26: 110-7.
- 329 3. Zimmermann MB. The adverse effects of mild-to-moderate iodine deficiency during pregnancy
330 and childhood: a review. *Thyroid.* 2007;17: 829–835.
- 331 4. Clark C, Sörqvist P. A 3 year update on the influence of noise on performance and behavior.
332 *Noise Health.* 2012;14: 292-296.

- 333 5. Anand VT, Mann SB, Dash RJ, Mehra YN. Auditory investigations in hypothyroidism. *Acta*
334 *Otolaryngol.* 1989;108: 83-7.
- 335 6. Malik V, Shukla GH, Bhatia N. Hearing profile in hypothyroidism. *Indian J Otolaryngol Head*
336 *Neck Surg.* 2002; 54: 285–290.
- 337 7. Sohmer H, Freeman S. The importance of thyroid hormone for auditory development in the
338 fetus and neonate. *Audiol Neurootol.* 1996;1: 137-147.
- 339 8. Graven SN, Browne JV. Auditory development in the fetus and infant. *Newborn Infant Nurs*
340 *Rev.* 2008;8: 187–193.
- 341 9. Knipper M, Richardson G, Mack A, Müller M, Goodyear R, Limberger A, et al. Thyroid
342 hormone-deficient period prior to the onset of hearing is associated with reduced levels of β -
343 tectorin protein in the tectorial membrane. Implications for hearing loss. *J Biol Chem.* 2001;
344 276: 39046–39052.
- 345 10. Wasniewska M, De Luca F, Siclari S, Salzano G, Messina MF, Lombardo F, et al. Hearing loss in
346 congenital hypothalamic hypothyroidism: a wide therapeutic window. *Hear Res.* 2002;172:
347 87–91.
- 348 11. Bradley DJ, Towle HC, Young WS. Alpha and beta thyroid hormone receptor (TR) gene
349 expression during auditory neurogenesis: evidence for TR isoform-specific transcriptional
350 regulation in vivo. *Proc Natl Acad Sci U S A.* 1994;91: 439–443.
- 351 12. Forrest, D. Deafness and goiter: molecular genetic considerations. *J Clin Endocrinol Metab.*
352 1996; 81: 2764–2767.
- 353 13. Bizhanova A, Kopp P. Controversies concerning the role of pendrin as an apical iodide
354 transporter in thyroid follicular cells. *Cell Physiol Biochem.* 2011;28: 485–490.
- 355 14. Brucker-Davis F, Skarulis MC, Grace MB, Benichou J, Hauser P, Wiggs E, et al. Genetic and
356 clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of
357 Health Prospective Study. *Ann Intern Med.* 1995;123: 572–583.

- 358 15. Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S. A novel syndrome combining
359 thyroid and neurological abnormalities is associated with mutations in a monocarboxylate
360 transporter gene. *Am J Hum Genet.* 2004;74: 168-75.
- 361 16. Coakley JC, Keir EH, Connelly JF. The association of thyroid dysmorphogenesis and deafness
362 (Pendred syndrome): experience of the Victorian Neonatal Thyroid Screening Programme. *J*
363 *Paediatr Child Health.* 1992;28: 398-401.
- 364 17. Bogazzi F, Russo D, Raggi F, Ultimieri F, Berrettini S, Forli F, et al. Mutations in the SLC26A4
365 (pendrin) gene in patients with sensorineural hearing loss and enlarged vestibular aqueduct.
366 *J Endocrinol Invest.* 2004;27: 430–435.
- 367 18. Wémeau JL, Kopp P. Pendred syndrome. *Best Pract Res Clin Endocrinol Metab.* 2017;31: 213-
368 224.
- 369 19. Comer DM, McConnell EM. Hypothyroid-associated sensorineuronal deafness. *Ir J Med Sci.*
370 2010;179: 621-2.
- 371 20. Bircher H. *Der Endemische Kropf.* Basel 1883.
- 372 **21.** Howarth AE, Lloyd HE. Perceptive deafness in hypothyroidism. *Br Med J.* 1956;1: 431-3.
- 373 **22.** Bhatia L, Gupta OP, Agrawal MK, Mishr SK. Audiological and vestibular function tests in
374 hypothyroidism. *Laryngoscope* 1977;87: 2082-9.
- 375 23. Aggarwal MK, Singh GB, Nag RK, Singh SK, Kumar R, Yadav M. Audiological Evaluation in
376 Goitrous Hypothyroidism. *Int J Otolaryngol Head Neck Surg.* 2013;2: 201-206.
- 377 **24.** Post JT. Hypothyroid deafness. A clinical study of sensori-neural deafness associated with
378 hypothyroidism. *Laryngoscope.* 1964;74: 221-32.
- 379 25. DeVos JA, Parving A, Ostri B, Bretlau P, Hansen JM, Parving HH. Audiological and temporal
380 bone findings in myxedema. *Ann Otol Rhinol Laryngol.* 1986;95: 278-83.
- 381 **26.** Balaji PV, Thirumaran M, Sharathbabu V. Assessment of audiologic evaluation in patients
382 with acquired hypothyroidism. *IAIM* 2016; 3(7): 222-227.

- 383 27. Santos KT, Dias NH, Mazeto GM, Carvalho LR, Lapate RL, Martins RH. Audiologic evaluation in
384 patients with acquired hypothyroidism. *Braz J Otorhinolaryngol.* 2010;76: 478-84.
- 385 28. Scinicariello F, Buser MC. Association of Iodine Deficiency with Hearing Impairment in US
386 Adolescents Aged 12 to 19 Years: Analysis of NHANES 2007-2010 Data. *JAMA Otolaryngol*
387 *Head Neck Surg.* 2018;144: 644-645.
- 388 29. Millon-Ramirez C, García-Fuentes E, Soriguer F. Iodine Deficiency and Hearing
389 Impairment. *JAMA Otolaryngol Head Neck Surg.* 2019;145:94–95.
- 390 30. Zamrazil V, Bilek R, Cerovska J, Delange F. The elimination of iodine deficiency in the Czech
391 Republic: the steps toward success. *Thyroid* 2004;14: 49-56.
- 392 31. World Health Organization 2007. Assessment of Iodine Deficiency Disorders and Monitoring
393 Their Elimination: A Guide for Programme Managers 3rd ed. Geneva, Switzerland: World
394 Health Organization; 2007. Available from:
395 http://apps.who.int/iris/bitstream/10665/43781/1/9789241595827_eng.pdf.
- 396 32. Skevington SM, Lotfy M, O'Connell KA; WHOQOL Group. The World Health Organization's
397 WHOQOL-BREF quality of life assessment: psychometric properties and results of the
398 international field trial. A report from the WHOQOL group. *Qual Life Res.* 2004;13: 299-310.
- 399 33. Hoffman HJ, Dobie RA, Losonczy KG, Themann CL, Flamme GA. Declining prevalence of hearing
400 loss in US adults aged 20 to 69 years. *JAMA Otolaryngol Head Neck Surg.* 2017;143: 274-285.
- 401 34. GBD 2019 Hearing Loss Collaborators. Hearing loss prevalence and years lived with disability,
402 1990-2019: findings from the Global Burden of Disease Study 2019. *Lancet* 2021;397: 996-
403 1009.
- 404 35. Meloun M, Hill M, Militky J, Kupka K. Transformation in the PC-aided biochemical data analysis.
405 *Clin Chem Lab Med.* 2000;38: 553-9.
- 406 36. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. *Lancet.* 2017 23;390: 1550-
407 1562.

- 408 37. Taylor, P., Albrecht, D., Scholz, A. et al. Global epidemiology of hyperthyroidism and
409 hypothyroidism. *Nat Rev Endocrinol.* 2018;14: 301-316.
- 410 38. Graydon K, Waterworth C, Miller H, Gunasekera H. Global burden of hearing impairment and
411 ear disease. *J Laryngol Otol.* 2019;133: 18-25.
- 412 39. Jung SY, Kim SH, Yeo SG. Association of Nutritional Factors with Hearing Loss. *Nutrients.*
413 2019;11: 307.
- 414 40. Lin FR, Yaffe K, Xia J, Xue QL, Harris TB, Purchase-Helzner E, et al. Hearing loss and cognitive
415 decline in older adults. *JAMA Intern. Med.* 2013;173: 293-299.
- 416 41. Kim SH, Won YS, Kim MG, Baek YJ, Oh IH, Yeo SG. Relationship between obesity and hearing
417 loss. *Acta Otolaryngol.* 2016;136: 1046–1050.
- 418 42. Singh R, Aftab M, Jain S, Kumar D. Audiological Evaluation in Hypothyroid Patients and Effect
419 of Thyroxine Replacement Therapy. *Indian J Otolaryngol Head Neck Surg.* 2019;71: 548-552.
- 420 43. Mahfzah M, Alhawari H, Momani SM, Abbasi H. The prevalence of hearing loss in patients
421 with autoimmune thyroid disease: A prospective study. *Jordan Medical Journal.* 2018; 52:
422 109-116.
- 423 44. Vant Hoff W, Stuard DW. Deafness in myxedema. *O J Med.* 1979; 48: 361-7.
- 424 45. Knudsen N, Bulow I, Jørgensen T, Perrild H, Ovesen L, Laurberg P. Serum Tg: a sensitive
425 marker of thyroid abnormalities and iodine deficiency in epidemiological studies. *J Clin*
426 *Endocrinol Metab.* 2001;86: 3599-3603.
- 427 46. Iodine Global Network (2016) Global scorecard 2016: moving toward optimal iodine status.
428 Available from: http://www.ign.org/newsletter/idd_nov16_global_scorecard_2016.pdf.
- 429 47. Chen ZP, Hetzel BS. Cretinism revisited. *Best Pract Res Clin Endocrinol Metab.* 2010;24: 39-
430 50.
- 431 48. Kessler JH. The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia.
432 *Breast J.* 2004;10: 328-336.

433 49. Salas-Lucia F, Bianco AC. T3 levels and thyroid hormone signaling. Front Endocrinol
434 (Lausanne). 2022;13: 1044691.

435

436 **Funding**

437 This research was funded by a grant from the Ministry of Health, Czech Republic—
438 conceptual development of a research organization (Institute of Endocrinology—EU,
439 00023761).

440